DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION

DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION
CDER/OPQ/OPMA/Division of Biotechnology Manufacturing 10903 New Hampshire Avenue; White Oak Building 51, Room 2269 Silver Spring, MD 20993 E-mail: OPMABLAInspection483Responses@fda.hhs.gov	01/08/2025-01/16/2025
	FEI NUMBER 3003195501

NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED
Dr. Caroline Blechschmidt, Site Quality Head

FIRM NAME	STREET ADDRESS
Sanofi-Aventis Deutschland GmbH	Industriepark Hochst, Bruningstr. 50
CITY, STATE, ZIP CODE, COUNTRY Frankfurt Am Main, 65926, Germany	TYPE ESTABLISHMENT INSPECTED Drug Substance and Drug Product

This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective actions in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.

DURING AN INSPECTION OF YOUR FIRM WE OBSERVED:

OBSERVATION 1

Procedures designed to prevent microbiological contamination of [redacted] or [redacted] drug products purporting to be sterile are not established and followed.

A. Environmental monitoring of critical surfaces following aseptic filling operations are deficient.
   i. Microbiological surface sampling of the product contact [redacted] is not performed on [redacted] filling lines in building [redacted]
   ii. Microbiological surface sampling of secondary product contact parts including the [redacted] contact parts and open [redacted] contact parts are not performed after a [redacted] campaign or [redacted] campaign on [redacted] or [redacted] filling lines.

B. Inadequate aseptic processing technique was observed during the activities performed in [redacted] in Building [redacted] during [redacted] setup and filling operations. Non-sterile [redacted] gloves were used to handle the [redacted] and [redacted] tubing and the [redacted] during their connection and installation. Additionally, during this process first air was blocked above the exposed [redacted]

C. There is no assurance that the secondary product contact surfaces which are not sterilized (such as [redacted] gloves, [redacted] and the [redacted] are adequately cleaned, as verified by sampling at worst case (hardest to clean) locations, prior to the [redacted] cycle on [redacted] or [redacted] filling lines.

D. During [redacted] validation and revalidation of [redacted] for fill lines [redacted] biological indicator (BI) was placed next to the [redacted] within the bag and [redacted] The [redacted] BI placements during [redacted] validation do not ensure that the [redacted] inactivating the [redacted] BIs enters through the [redacted] and reaches all product-contact surfaces and thus, the sterility of the [redacted] is not assured.

E. The identified pinholes in the [redacted] gloves compromise the integrity of the [redacted] in [redacted] exposing the Grade A environment to potential contamination from the Grade D

SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE	EMPLOYEE(S) NAME AND TITLE *(Print or Type)*	DATE ISSUED
	Madushini N. Dharmasena -S Digitally signed by Madushini N. Dharmasena -S Date: 2025.01.16 08:50:32 -05'00'	Madushini Dharmasena, Ph.D., Senior Pharmaceutical Quality Assessor Michal Levine Millrod, Ph.D., Pharmaceutical Scientist Rachel Lokanga, Ph.D., Interdisciplinary Scientist	01/16/2025

environment and thus, the sterility of the [redacted] may not be assured during [redacted] and [redacted] filling.

OBSERVATION 2

[redacted] DS manufacturing area is not under control to assure product quality. [redacted] DS manufacturing process from [redacted] ([redacted] are performed in an area of the [redacted] Building [redacted] that is classified as zone [redacted] The area is equipped with only basic temperature controls and lacks systems for pressure and humidilty control and environmental monitoring.

OBSERVATION 3

[redacted] or [redacted] not [redacted] are used for [redacted] storage, [redacted] and [redacted] of all [redacted] during [redacted] DS manufacturing process. Although Step [redacted] Use of [redacted] of the [redacted] step (Step [redacted] does not assure product quality for an [redacted] product as the [redacted] generation process is less stringent than the [redacted] generation.

OBSERVATION 4

There is a lack of assurance that the cleaning procedures used for product-contact process equipment for the manufacture of [redacted] DP and [redacted] DS and DP are effective in preventing product carryover and cross-contamination.

A. Swab sampling is not performed during cleaning validation of multi-product use [redacted] or dedicated [redacted] during DP manufacturing.
B. The swab sampling is not performed during cleaning validation of [redacted] DS downstream manufacturing vessels.